Spatially Fractionated Radiation Therapy (SFRT) is a radiation therapy technique that allows for safe dose escalation for radiation for radiation treatment. Specialized beam collimation creates high-dose peaks organized throughout a target volume with intervening low-dose valleys. Pre-clinical animal studies have shown that with a single dose of SFRT there is much lower toxicity, good tumor control, and employs the patients own immunity to fight the tumor/cancer.
NuVeta will deliver beams 0.5mm thin. This will allow NuVeta to harvest all the benefits of safe SFRT that would be consistent with the previous animal studies and repeat the same results in humans.
Pre-clinical animal studies have shown that with a single dose of RT there is much lower toxicity, good tumor control, and it employs the patient’s own immunity to fight the tumor/cancer. Pre-clinical SFRT data shows the tissue sparing MRT radiation is tumor controlling.
Current SFRT radiation beams are too broad/wide at 10-20mm, creating too much damage with a large radiation footprint. NuVeta will deliver beams 0.5mm thin. This will allow NuVeta to fully harvest all the benefits of safe SFRT that would be consistent with the previous animal studies and repeat the same results in humans.
At NuVeta Radiotherapy, we have a strong management team and scientific board composed of individuals who have a wide range of skills and experience. With strong leadership in place, we are well positioned to achieve our goals and drive the success of the company.
Chief Executive Officer
Chief Scientific Officer
Chief Technology Officer
Chief Nano Technology Officer
Chief Financial Officer
VP of Business Development
Chief Medical Officer &
Chief Operating Officer
PhD, FAAPM
DVM, PhD
PharmD, PhD
M.D.